ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Johnson and Johnson

Johnson and Johnson (JNJ)

152.61
-0.57
(-0.37%)
152.27
-0.34
( -0.22% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
152.27
Bid
-
Ask
-
Volume
4,420
0.00 Day's Range 0.00
141.08 52 Week Range 169.99
Market Cap
Previous Close
152.61
Open
-
Last Trade
2
@
152.08
Last Trade Time
07:55:27
Financial Volume
-
VWAP
-
Average Volume (3m)
9,568,351
Shares Outstanding
2,406,073,279
Dividend Yield
3.41%
PE Ratio
26.11
Earnings Per Share (EPS)
5.85
Revenue
88.82B
Net Profit
14.07B

About Johnson and Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New Brunswick, New Jersey, USA
Founded
-
Johnson and Johnson is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker JNJ. The last closing price for Johnson and Johnson was $152.61. Over the last year, Johnson and Johnson shares have traded in a share price range of $ 141.08 to $ 169.99.

Johnson and Johnson currently has 2,406,073,279 shares outstanding. The market capitalization of Johnson and Johnson is $367.19 billion. Johnson and Johnson has a price to earnings ratio (PE ratio) of 26.11.

Johnson and Johnson (JNJ) Options Flow Summary

Overall Flow

Bearish

Net Premium

-12M

Calls / Puts

156.25%

Buys / Sells

87.50%

OTM / ITM

86.36%

Sweeps Ratio

0.00%

JNJ Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.421.61494828161149.85154.43149.228517014152.60779081CS
4-2.05-1.32840850181154.32158.2146.1157948421153.25125808CS
12-11.73-7.15243902439164169.99141.59568351157.34320873CS
26-3.13-2.01415701416155.4169.99141.089111635154.13937141CS
52-0.65-0.425058854303152.92169.99141.087877549155.14421775CS
156-25.33-14.2623873874177.6183.3506141.088705632161.46086504CS
2606.084.15897120186146.19186.69133.658082033161.47148626CS

JNJ - Frequently Asked Questions (FAQ)

What is the current Johnson and Johnson share price?
The current share price of Johnson and Johnson is $ 152.27
How many Johnson and Johnson shares are in issue?
Johnson and Johnson has 2,406,073,279 shares in issue
What is the market cap of Johnson and Johnson?
The market capitalisation of Johnson and Johnson is USD 367.19B
What is the 1 year trading range for Johnson and Johnson share price?
Johnson and Johnson has traded in the range of $ 141.08 to $ 169.99 during the past year
What is the PE ratio of Johnson and Johnson?
The price to earnings ratio of Johnson and Johnson is 26.11
What is the cash to sales ratio of Johnson and Johnson?
The cash to sales ratio of Johnson and Johnson is 4.13
What is the reporting currency for Johnson and Johnson?
Johnson and Johnson reports financial results in USD
What is the latest annual turnover for Johnson and Johnson?
The latest annual turnover of Johnson and Johnson is USD 88.82B
What is the latest annual profit for Johnson and Johnson?
The latest annual profit of Johnson and Johnson is USD 14.07B
What is the registered address of Johnson and Johnson?
The registered address for Johnson and Johnson is ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NEW JERSEY, 08933
What is the Johnson and Johnson website address?
The website address for Johnson and Johnson is www.jnj.com
Which industry sector does Johnson and Johnson operate in?
Johnson and Johnson operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZKHZKH Group Limited
$ 3.49
(12.76%)
2
SMRNuScale Power Corporation
$ 27.80
(9.79%)
1.18M
OKLOOklo Inc
$ 43.44
(9.37%)
3.07M
AVALGrupo Aval Acciones y Valores SA
$ 2.99
(9.12%)
5
NXENexGen Energy Ltd
$ 5.92
(8.82%)
58.69k
DECKDeckers Outdoor
$ 102.59
(-18.64%)
299.26k
MNSOMINISO Group Holding Limited
$ 19.02
(-14.29%)
305.64k
BAHBooz Allen Hamilton Holding Corporation
$ 115.00
(-10.94%)
41.25k
EAFGrafTech International Ltd
$ 0.863
(-10.17%)
55
IONQIonQ Inc
$ 43.35
(-5.33%)
1.89M
QBTSD Wave Quantum Inc
$ 18.34
(-3.68%)
5.29M
OKLOOklo Inc
$ 43.39
(9.24%)
3.06M
IONQIonQ Inc
$ 43.43
(-5.15%)
1.83M
BBAIBigBear ai Holdings Inc
$ 3.85
(0.79%)
1.25M
SMRNuScale Power Corporation
$ 27.76
(9.64%)
1.17M

JNJ Discussion

View Posts
BottomBounce BottomBounce 5 days ago
"This is the stuff they wanted you to inject.

Blood begins clotting within seconds of adding the Janssen COVID-19 vaccine to a blood sample." $JNJ This is the stuff they wanted you to inject.

Blood begins clotting within seconds of adding the Janssen COVID-19 vaccine to a blood sample. pic.twitter.com/bdhFkIpNFO— Steve 🇺🇸 (@SteveLovesAmmo) April 28, 2023
👍️0
BottomBounce BottomBounce 1 week ago
🚨ACCOUNTABILITY AND JUSTICE INCOMING🚨

✅11 U.S. states have legislative efforts to BAN mRNA injections

✅Criminal referrals filed in 7 states against Fauci & top COVID officials — accused of murder, racketeering, fraud & terrorism. 2 active criminal investigations are already… pic.twitter.com/Ra6xgYUQTY— Nicolas Hulscher, MPH (@NicHulscher) May 14, 2025 $JNJ
👍️0
theOGInvestor theOGInvestor 1 week ago
$JNJ Great buy opportunity. Long history of dividend income stream, combined with the ability to be somewhat insulated from tariff uncertainty. Offers the best combination of safety and capital gain potential.
Check out my latest blog to get a comprehensive analysis and a DCF model intrinsic value: just published: just published: JNJ Fundamental Analysis Report
👍️0
Monksdream Monksdream 1 month ago
JNJ, 10Q due Tuesday 4/15
👍️0
BottomBounce BottomBounce 2 months ago
$JNJ Total Debt (mrq) $37.83B
👍️0
BottomBounce BottomBounce 2 months ago
Johnson & Johnson (J&J) has faced numerous lawsuits related to its talcum powder products, alleging that they contain asbestos and cause cancer.
Talcum Powder Lawsuits:
Claims:
Plaintiffs claim that J&J's talcum powder products contained asbestos, a known carcinogen, and that they developed ovarian cancer, mesothelioma, or other health problems as a result.
Current Status:
As of March 2025, there are over 58,000 talcum powder lawsuits pending against J&J. In 2024, J&J proposed a $10 billion settlement to resolve the lawsuits. The proposal is currently under review by a bankruptcy court.
Previous Settlements:
J&J has already settled thousands of talcum powder lawsuits for billions of dollars. In 2018, a Missouri jury awarded $4.14 billion in damages to 22 women who claimed their ovarian cancer was caused by J&J's baby powder.
Other Lawsuits:
Opioid Crisis: J&J is also facing lawsuits related to the opioid crisis, alleging that it contributed to the epidemic by aggressively marketing its prescription opioids.
Hip Implant Defects: J&J's DePuy division has faced lawsuits over defective hip implants.
Outlook:
The talcum powder lawsuits against J&J are likely to continue for some time. The outcome of the proposed $10 billion settlement is uncertain, and it is possible that more lawsuits will be filed. J&J's other legal battles, such as those related to opioids and hip implants, are also ongoing. $JNJ
👍️0
Chrism0000 Chrism0000 3 months ago
They need!! To buy!!! UEEC !!!!
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
Potential Acquisition of MindMed by J&J or Similar Pharma Companies:

Given Johnson & Johnson’s (J&J) recent acquisition of Intra-Cellular Therapies (ITCI) and its Phase 2 asset for Generalized Anxiety Disorder (GAD), the possibility of J&J or another major pharmaceutical company acquiring MindMed is a realistic scenario.
Why MindMed is an Attractive Acquisition Target

Psychedelic-Based Innovation – MindMed’s MM-120 (LSD-derived treatment) represents a novel approach to GAD that could complement or even disrupt traditional pharmacological treatments. Major pharma companies, including J&J, have been exploring psychedelic-based treatments, evidenced by their previous work with Spravato (esketamine) for depression.

Regulatory Progress and Phase 3 Trials – MM-120 is already in Phase 3 clinical trials and has received Breakthrough Therapy Designation from the FDA. A successful Phase 3 outcome would make MindMed a highly attractive buyout target, as acquiring a late-stage asset could be more efficient than developing a new one in-house.

Market Differentiation – J&J’s acquisition of ITCI suggests they are seeking broader control over the GAD treatment market. However, ITI-1284 operates through a traditional neuropsychiatric mechanism, whereas MM-120 offers a radically different approach via serotonergic psychedelics. This divergence could make MM-120 a highly valuable asset for any pharma company looking to hedge their neuroscience portfolio with a potentially revolutionary treatment.

Big Pharma’s Need for Pipeline Expansion – Large pharmaceutical companies, including J&J, Pfizer, and Merck, are continuously searching for promising late-stage clinical assets to maintain revenue streams as existing drug patents expire. The psychedelic medicine space is emerging as a major area of interest, especially as more clinical data supports the long-term efficacy and safety of these compounds.

Challenges and Considerations

Regulatory Uncertainty – Despite promising trial results, psychedelic-based therapies still face regulatory hurdles and stigma. J&J or another major pharma company may wait until MM-120 secures full FDA approval before making a move.

Cultural Fit and Integration – MindMed is structured as a high-risk, high-reward biotech firm focusing on psychedelic medicine. A large pharmaceutical company might hesitate to fully integrate this approach into a more traditional CNS pipeline.

Competition from Other Pharma Companies – While J&J could be a strong contender to acquire MindMed, other companies with neuroscience portfolios (e.g., AbbVie, Novartis, or Biogen) could also see MM-120 as an opportunity to expand into the psychedelic treatment space.

Conclusion: Likelihood of Acquisition

A J&J acquisition of MindMed is not out of the question, especially given J&J’s ongoing commitment to CNS treatments and GAD. However, whether J&J makes a move could depend on:

The success of MM-120’s Phase 3 trials
Market receptiveness to psychedelic-based treatments
Competitive interest from other pharmaceutical giants

If MM-120 demonstrates clear clinical efficacy and FDA approval seems likely, MindMed will almost certainly become a prime acquisition target in the next 12–24 months. J&J, given its recent neuroscience expansion, could be a logical suitor, but other pharma companies in the CNS space could also enter the fray, making a competitive bidding scenario plausible.
👍️0
Monksdream Monksdream 4 months ago
JNJ, 10q due 1/22
👍️0
MomsSpaghetti MomsSpaghetti 4 months ago
Oddly since posting this MindMed is looking at JNJ Spravato clinics to commercialize their MM-120 drug once FDA approved.

I bet they scoop them up.

Look at their last company presentation.
👍️0
MomsSpaghetti MomsSpaghetti 4 months ago
Seen that hoping JNJ (or someone) buying MNMD... We are getting close to some interesting acquisitions in this space.
👍️0
north40000 north40000 4 months ago
Correction: $14.6 billion.
👍️0
north40000 north40000 4 months ago
JNJ buys ITCI for ~ 4.8 Billion.
👍️0
BottomBounce BottomBounce 4 months ago
Johnson & Johnson $JNJ Total Debt (mrq) $35.75B
👍️0
MomsSpaghetti MomsSpaghetti 5 months ago
J&J has been involved in psychiatric drug development for decades and might be interested in psychedelic therapies as a way to differentiate their mental health offerings. J&J's Janssen division has explored the use of psychedelic compounds, such as in their work with esketamine (Spravato), a nasal spray approved for treatment-resistant depression. This makes J&J a potential acquirer for MindMed if the company wants to delve further into psychedelic-based treatments.

Thoughts on that?
👍️0
IHuser IHuser 7 months ago
imo... when my blonde haired comb over fat hero put the CEO of this pos out there to address the masses pushing vaccines.... I thought maybe he was playing th'old 4D Chess move.... they did not know I was playing 5D.


JNJ



IHuser
👍️0
EarningsCentral EarningsCentral 7 months ago
👍️0
Monksdream Monksdream 7 months ago
JNJ 10Q due OCTOBER 15
👍️0
IHuser IHuser 9 months ago
DNFWM........I am Christ and and I will cast you to hell if you fuck with me period~
👍️0
Monksdream Monksdream 10 months ago
JNJ 10Q due JULY17
👍️0
avxl_going_long avxl_going_long 1 year ago
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
Monksdream Monksdream 1 year ago
JNJ 10Q due 4/16
👍️0
BottomBounce BottomBounce 1 year ago
$JNJ has Total Debt (mrq) $29.92B
👍️0
IHuser IHuser 2 years ago
imo..... i have toppled bf starting w the evil worthless king flying red bull ace....those paying attention have watched in dismay...next!


JNJ PFE

IHuser
👍️0
IHuser IHuser 2 years ago
imo... this ticker is a toxic POS...FOLOW MY GROUP at PFE....


IHuser
👍️0
IHuser IHuser 2 years ago
imo...my global following will crash this stock.....and me....JNJ
👍️0
IHuser IHuser 2 years ago
imo.... if you are bullish on this ticker i will ruin you and your whole life....f with me JNJ


IHuser
👍️0
DewDiligence DewDiligence 2 years ago
JNJ’s KVUE spin-off now has its own iHub board:

https://investorshub.advfn.com/Kenvue-Inc-KVUE-42070
👍️0
1jas 1jas 2 years ago
anyone here, read about enzolytics pharm announcing the now have a cure for hiv/aids called clone 3 yesterday.
👍️0
Enterprising Investor Enterprising Investor 2 years ago
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer (8/21/23)

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer, 8.0324 shares of Kenvue common stock will be exchanged for each share of Johnson & Johnson common stock accepted in the exchange offer.

According to the exchange agent, Computershare Trust Company, N.A., 802,707,331 shares of Johnson & Johnson common stock were validly tendered and not validly withdrawn, including 250,407,279 shares that were tendered by notice of guaranteed delivery. Johnson & Johnson intends to accept 190,955,436 of the tendered shares in exchange for the 1,533,830,450 shares of Kenvue common stock owned by Johnson & Johnson. Because the exchange offer was oversubscribed, Johnson & Johnson is accepting only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Johnson & Johnson common stock, or an "odd-lot," who have validly tendered all of their shares, will not be subject to proration, in accordance with the terms of the exchange offer.

Based on the total number of shares of Johnson & Johnson common stock reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 23.8% of the tendered shares of Johnson & Johnson common stock will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures, as well as the number of "odd-lot" shares that were validly tendered and are not subject to proration. Johnson & Johnson expects to announce the final proration factor on August 23, 2023, promptly following the expiration of the guaranteed delivery period. Shares of Johnson & Johnson common stock tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

https://www.businesswire.com/news/home/20230821033927/en/Johnson-Johnson-Announces-Preliminary-Results-of-Kenvue-Inc.-Exchange-Offer
👍️0
Enterprising Investor Enterprising Investor 2 years ago
The Final Exchange Ratio is 8.0324 shares of KVUE per JNJ share (unless extended).

https://www.sec.gov/Archives/edgar/data/200406/000162828023029851/vwapday19.htm
👍️0
IHuser IHuser 2 years ago
imo... this ticker is culpable as any poisoning people...JNJ










IHuser
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 2 years ago
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 2 years ago
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 2 years ago
Nice long run
👍️0
fung_derf fung_derf 2 years ago
And.....?
👍️0
DewDiligence DewDiligence 2 years ago
Bankruptcy judge tosses JNJ’s proposed talc settlement:

https://www.wsj.com/articles/johnson-johnsons-second-talc-bankruptcy-case-thrown-out-74a63a13 A New Jersey bankruptcy judge threw out the second chapter 11 case that Johnson & Johnson filed to resolve its mass talc liabilities, again shutting down the healthcare-product company’s plan to achieve an $8.9 billion settlement [see #msg-171617699].

Judge Michael Kaplan of the U.S. Bankruptcy Court in Trenton, N.J., said that J&J affiliate LTL Management LLC, created to carry the company’s talc-related liabilities into bankruptcy, wasn’t in sufficient financial distress to warrant granting it the legal protections of chapter 11.
👍️0
DewDiligence DewDiligence 2 years ago
JNJ launches tax-free exchange offer for KVUE:

https://www.businesswire.com/news/home/20230723805654/en
👍️0
BottomBounce BottomBounce 2 years ago
J&J Vaccine and Guillain-Barré Syndrome: Information on the FDA Warning
https://www.yalemedicine.org/news/covid-vaccine-guillain-barre-syndrome $JNJ
👍️0
BottomBounce BottomBounce 2 years ago
Johnson & Johnson $JNJ Total Debt (mrq) $52.91B
👍️0
Agoura Guy Agoura Guy 2 years ago
***US FDA Revokes Emergency Use Authorization of J&J COVID-19 Vaccine***

***serious risk of blood clots***

TOO MANY DEAD PEOPLE.... JNJ KILLED TO MANY PATIENTS WITH THIS EXPERIMENTAL VACCINE POISON THAT HAD NO LONG TERM SAFETY TESTING!!!!!!

JNJ IS LIABLE FOR KILLING ALL THOSE INNOCENT PEOPLE!!!!!!

THESE CRIMINALS WILL BE SUED INTO OBLIVION!!!!!!!

SHORT THIS RANCID STOCK!!!!!!!!!


👍️ 1
DewDiligence DewDiligence 2 years ago
BMY/JNJ—Milvexian—>FDA Fast Track designation for_all_phase-3_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three Milvexian indications BMY/JNJ are pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF—see #msg-171338375.

FDA Fast Track status doesn’t mean much, but it makes a Priority Review of the NDAs somewhat more likely (if one or more of these phase-3 trials pan out).

Please see #msg-169818942 for additional background info.

p.s. This PR was issued yesterday.
👍️0
DewDiligence DewDiligence 2 years ago
JNJ’s talc settlement encounters a hitch:

https://endpts.com/talc-claimants-look-to-sue-jj-over-alleged-fraud-in-bankruptcy-case/
👍️0
DewDiligence DewDiligence 2 years ago
KVUE +22% on_first_day_of_trading, valuing_the_company_at ~$50B.
👍️0
DewDiligence DewDiligence 2 years ago
JNJ consumer spinoff, Kenvue IPOs @$22.00—starts_trading_today_as KVUE:

https://finance.yahoo.com/news/kenvue-begin-trading-york-stock-132500217.html

At the IPO price, KVUE’s market cap is ~$41B. Following the IPO, JNJ still owns about 90% of KVUE and plans to distribute the remainder to JNJ shareholders at some point.

Caution: KVUE bears 100% of JNJ’s talc liability outside of the US and Canada.
👍️0
Agoura Guy Agoura Guy 2 years ago
Holding Big Pharma ACCOUNTABLE: J & J To Pay Victims $8.9 Billion For Cancer Causing Baby Powder!!!!!

WHAT KIND OF MONSTERS RUN J & J?????

SMEARING CANCER ON BABIES???????

SHORT THIS CRAP TO OBLIVION!!!!!!!

👍️ 1
DewDiligence DewDiligence 2 years ago
Addendum—JNJ’s ex-North America talc liabilities are being transferred to the Kenvue spinoff, according to Kenvue’s SEC filings.
👍️0
DewDiligence DewDiligence 2 years ago
JNJ asserts_it_has_settled_North_America talc claims_for_an NPV_of_$8.9B_spread_over_25_years:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000200406/000020040623000037/jnj-20230404.htm On April 4, 2023, the Company announced that its wholly owned subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will efficiently resolve all current and future claims arising from cosmetic talc litigation against the Company and its affiliates in North America. The Company has agreed to contribute up to the present value of $8.9 billion over 25 years (nominal value approximately $12 billion) to resolve the North America talc claims… JNJ’s press release (https://www.sec.gov/Archives/edgar/data/200406/000020040623000037/a44238-kexhibit991.htm ) says: LTL also has secured commitments from over 60,000 current claimants to support a global resolution on these terms. Notably, the PR doesn’t say how many other ex-North America claimants there are (or will be) and what is meant by the phrase, “these terms.”
👍️0
DewDiligence DewDiligence 2 years ago
JNJ has earmarked $61.5B for talc liability, according to court documents:

https://www.fiercepharma.com/pharma/after-johnson-johnson-loses-again-bankruptcy-case-its-game-talc-lawsuits
👍️0
IHuser IHuser 2 years ago
imo...Mr. Putin and the white hat US are dropping these criminals...thank-you..from USA___JNJ
👍️0

Your Recent History

Delayed Upgrade Clock